209 related articles for article (PubMed ID: 35660951)
1. Adverse outcome pathway from activation of the AhR to breast cancer-related death.
Benoit L; Jornod F; Zgheib E; Tomkiewicz C; Koual M; Coustillet T; Barouki R; Audouze K; Vinken M; Coumoul X
Environ Int; 2022 Jul; 165():107323. PubMed ID: 35660951
[TBL] [Abstract][Full Text] [Related]
2. AOP-helpFinder 2.0: Integration of an event-event searches module.
Jaylet T; Coustillet T; Jornod F; Margaritte-Jeannin P; Audouze K
Environ Int; 2023 Jul; 177():108017. PubMed ID: 37295163
[TBL] [Abstract][Full Text] [Related]
3. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
[TBL] [Abstract][Full Text] [Related]
4. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
[TBL] [Abstract][Full Text] [Related]
5. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
[TBL] [Abstract][Full Text] [Related]
6. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.
Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T
Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
[TBL] [Abstract][Full Text] [Related]
8. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
[TBL] [Abstract][Full Text] [Related]
9. AOP Report: Aryl Hydrocarbon Receptor Activation Leads to Early-Life Stage Mortality via Sox9 Repression-Induced Craniofacial and Cardiac Malformations.
Shankar P; Villeneuve DL
Environ Toxicol Chem; 2023 Oct; 42(10):2063-2077. PubMed ID: 37341548
[TBL] [Abstract][Full Text] [Related]
10. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.
Sachana M; Rolaki A; Bal-Price A
Toxicol Appl Pharmacol; 2018 Sep; 354():153-175. PubMed ID: 29524501
[TBL] [Abstract][Full Text] [Related]
11. Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia.
Itkonen A; Hakkola J; Rysä J
Arch Toxicol; 2023 Nov; 97(11):2861-2877. PubMed ID: 37642746
[TBL] [Abstract][Full Text] [Related]
12. Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease.
Del'haye GG; Nulmans I; Bouteille SP; Sermon K; Wellekens B; Rombaut M; Vanhaecke T; Vander Heyden Y; De Kock J
Arch Toxicol; 2022 Nov; 96(11):2881-2897. PubMed ID: 35927586
[TBL] [Abstract][Full Text] [Related]
13. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
[TBL] [Abstract][Full Text] [Related]
14. [Molecular Pathway and AOP Development Using Gene Network Analysis].
Tanabe S; Hirose A; Whelan M; Yamada T
Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
[TBL] [Abstract][Full Text] [Related]
15. Developing adverse outcome pathways on silver nanoparticle-induced reproductive toxicity via oxidative stress in the nematode Caenorhabditis elegans using a Bayesian network model.
Jeong J; Song T; Chatterjee N; Choi I; Cha YK; Choi J
Nanotoxicology; 2018 Dec; 12(10):1182-1197. PubMed ID: 30663905
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
[TBL] [Abstract][Full Text] [Related]
17. A Case Study on Integrating a New Key Event Into an Existing Adverse Outcome Pathway on Oxidative DNA Damage: Challenges and Approaches in a Data-Rich Area.
Huliganga E; Marchetti F; O'Brien JM; Chauhan V; Yauk CL
Front Toxicol; 2022; 4():827328. PubMed ID: 35573276
[TBL] [Abstract][Full Text] [Related]
18. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
[TBL] [Abstract][Full Text] [Related]
19. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
[TBL] [Abstract][Full Text] [Related]
20. Expert consultation is vital for adverse outcome pathway development: a case example of cardiovascular effects of ionizing radiation.
Chauhan V; Hamada N; Monceau V; Ebrahimian T; Adam N; Wilkins RC; Sebastian S; Patel ZS; Huff JL; Simonetto C; Iwasaki T; Kaiser JC; Salomaa S; Moertl S; Azimzadeh O
Int J Radiat Biol; 2021; 97(11):1516-1525. PubMed ID: 34402738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
